A Smart Paclitaxel-Disulfiram Nanococrystals for Efficient MDR Reversal and Enhanced Apoptosis
- PMID: 29488114
- DOI: 10.1007/s11095-018-2370-0
A Smart Paclitaxel-Disulfiram Nanococrystals for Efficient MDR Reversal and Enhanced Apoptosis
Abstract
Purpose: A multidrug resistance (MDR) modulator, disulfiram (DSF), was incorporated into pure paclitaxel (PTX) nanoparticles to construct a smart paclitaxel-disulfiram nanococrystals (PTX-DSF Ns) stabilized by β-lactoglobulin (β-LG), with the aim to reverse MDR and therefore enhnce cytotoxicity towards Taxol-resistant A549 cells (A549/TAX).
Method: PTX-DSF Ns was prepared by antisolvent precipitation method. Flow cytometry was used to determine the cell uptake, drug efflux inhibition, cell cycle phase arrest and apoptosis. MDR-1 gene expression level was detected by real time quantitative PCR and gel electrophoresis.
Results: PTX-DSF Ns prepared from the optimized formulation had an optimum diameter of 160 nm, was stable and had a high drug-loading capacity. Importantly, the uptake of PTX-DSF Ns in A549/TAX cells was 14-fold greater than the uptake of PTX Ns. Furthermore, PTX-DSF Ns promoted 5-folds increase in apoptosis, enabled 7-folds reduction in the IC50, and rendered 8.9-fold decrease in the dose compared with free PTX.
Conclusion: PTX-DSF Ns with a precise mass ratio offer efficient cytotoxicity against Taxol-resistant cells and a novel approach for codelivery and sensitizing MDR cancer to chemotherapy. In addition, the use of nanosuspensions as a combined treatment provides a new research avenue for nanosuspensions.
Keywords: apoptosis; combined therapy; multidrug resistance; nanosuspensions; p-glycoprotein.
Similar articles
-
Drug-delivering-drug approach-based codelivery of paclitaxel and disulfiram for treating multidrug-resistant cancer.Int J Pharm. 2019 Feb 25;557:304-313. doi: 10.1016/j.ijpharm.2018.12.067. Epub 2018 Dec 29. Int J Pharm. 2019. PMID: 30599232
-
Apatinib Reverses Paclitaxel-resistant Lung Cancer Cells (A549) Through Blocking the Function of ABCB1 Transporter.Anticancer Res. 2019 Oct;39(10):5461-5471. doi: 10.21873/anticanres.13739. Anticancer Res. 2019. PMID: 31570440
-
Folic Acid-Modified Nanoerythrocyte for Codelivery of Paclitaxel and Tariquidar to Overcome Breast Cancer Multidrug Resistance.Mol Pharm. 2020 Apr 6;17(4):1114-1126. doi: 10.1021/acs.molpharmaceut.9b01148. Epub 2020 Mar 23. Mol Pharm. 2020. PMID: 32176509
-
Therapeutic strategies to overcome taxane resistance in cancer.Drug Resist Updat. 2021 Mar;55:100754. doi: 10.1016/j.drup.2021.100754. Epub 2021 Feb 27. Drug Resist Updat. 2021. PMID: 33691261 Review.
-
Combating P-glycoprotein-mediated multidrug resistance using therapeutic nanoparticles.Curr Pharm Des. 2013;19(37):6655-66. doi: 10.2174/1381612811319370009. Curr Pharm Des. 2013. PMID: 23621532 Review.
Cited by
-
Advances in nanomedicine for the treatment of ankylosing spondylitis.Int J Nanomedicine. 2019 Oct 29;14:8521-8542. doi: 10.2147/IJN.S216199. eCollection 2019. Int J Nanomedicine. 2019. PMID: 31806960 Free PMC article. Review.
-
Nanomedicine-based disulfiram and metal ion co-delivery strategies for cancer treatment.Int J Pharm X. 2024 Apr 18;7:100248. doi: 10.1016/j.ijpx.2024.100248. eCollection 2024 Jun. Int J Pharm X. 2024. PMID: 38689600 Free PMC article. Review.
-
Recent advances in the delivery of disulfiram: a critical analysis of promising approaches to improve its pharmacokinetic profile and anticancer efficacy.Daru. 2019 Dec;27(2):853-862. doi: 10.1007/s40199-019-00308-w. Epub 2019 Nov 22. Daru. 2019. PMID: 31758497 Free PMC article. Review.
-
Pharmaceutical Dispersion Techniques for Dissolution and Bioavailability Enhancement of Poorly Water-Soluble Drugs.Pharmaceutics. 2018 Jun 23;10(3):74. doi: 10.3390/pharmaceutics10030074. Pharmaceutics. 2018. PMID: 29937483 Free PMC article. Review.
-
Homotype-Targeted Biogenic Nanoparticles to Kill Multidrug-Resistant Cancer Cells.Pharmaceutics. 2020 Oct 9;12(10):950. doi: 10.3390/pharmaceutics12100950. Pharmaceutics. 2020. PMID: 33050126 Free PMC article.
References
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous